F-star Therapeutics Long Term Debt

F-star Therapeutics (FSTX) currently reports a long-term debt of $11M as of September 2022. That compares with $12M in the prior-year period — down 15.1% year over year. Use the charts on this page to explore F-star Therapeutics's long-term debt history and peer comparisons.

F-star Therapeutics's long-term debt decreased from $12M to $11M — a 15.1% year-over-year decrease (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

F-star Therapeutics reported $11M in long-term debt as of September 2022. That compares with $12M in the prior-year period — down 15.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $11M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for F-star Therapeutics, and consider following FSTX for alerts when major investors trade the stock.

F-star Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $11M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FSTX with unrelated industries.